Advanced Malignant Solid Tumor
Conditions
Keywords
Neoantigen, Neoantigen Reactive T cells (NRTs), PD-1 Inhibitor, Advanced Solid Tumor, Adoptive Cell Therapy(ACT), PD-1 antibody, SHR1210
Brief summary
The purpose of this study is to see the safety and efficient of neoantigen reactive T cells (NRTs) combined with programmed cell death-1(PD-1) inhibitor（SHR-1210）in the treatment of Chinese patients with advanced refractory solid tumors.
Detailed description
The tumor-specific none-self immunogenic neoantigens encoded by either viral genes or somatic mutation genes, possess the potential to induce specific anti-cancer immunity, including cellular and humoral immune responses. Today, numerous clinical trials demonstrate that although these none-self antigens initiate the antigen-specific immunoglobulin G antibodies and cluster of differentiation 4（CD4）+/cluster of differentiation 8（CD8）+T-cells response, not all of them show a clinical benefit in the response rate, progression-free survival or overall survival.Immune tolerance induced by PD-1 or programmed cell death-ligand1（ PD-L1）maybe play a vital role for these negative outcomes.Personalized cell therapy plus checkpoint inhibitors maybe own a breakthrough in the treatment of those malignant diseases without standard options.Our center has successfully established a new method for preparing personalized neoantigen reactive T cells(NRTS) for adoptive cell therapy(ACT). Today, we will carry out a single center single arm clinical prospective study of NRTs combined with PD-1 inhibitor(SHR-1210) for the treatment of Chinese patients with advanced refractory solid tumors. Participants are assigned to receive 4 circles of cell therapy,and prior to each cycle's immunocytes treatment,preconditional chemotherapy and SHR-1210 will be carried out, and IL-2 continuous intravenous infusion（CIV） will also be given for 5 consecutive days after each time's cell infusion. The safety and clinical response rate（RR） are evaluated. Biomarkers and immunological markers are also monitored.
Interventions
BIOLOGICALNeoantigen Reactive T Cells(NRTs)
Neoantigen Reactive T Cells in an expected volume of 100 milliliter（mL） will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
BIOLOGICALSHR-1210
SHR-1210 200mg will be administered as an intravenous infusion over 60 minutes.
DRUGFludarabine
Fludarabine(FLU) 30mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
DRUGCyclophosphamide
Cyclophosphamide(CTX) 300mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
BIOLOGICALInterleukin-2
Interleukin-2(IL-2)will be continuous intravenous infused since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit per day.
Sponsors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Adult patients aged 18 to 75 years old * Histologic or cytologic confirmation of advanced refractory solid tumors with no available curative treatment options * At least one measurable disease: diameter ≥20mm or spiral computed tomography(CT)≥10mm; and can providing with tumor specimen (for testing the expression of PD -L1 and the infiltrating lymphocytes) * Must be human leukocyte antigen (HLA)-A2/A24/A11 positive * Eastern Cooperative Oncology Group(ECOG)\<0-2 and expected survival time 3 months or more * At least one new antigen can induce T cell secrete interferon - gamma (IFN - gamma) twice as normal controls during the new antigens screening * Without anticancer treatment more than one month * Hematology Index including: Neutrophile granulocyte greater than 1.5×10\^9/L; Hemoglobin greater than 10g/dL; Platelet greater than 100×10\^9/L * Biochemical index including: Serum bilirubin not greater than 1.5x upper limit of reference range (ULN); glutamic-pyruvic transaminase（ALT） or glutamic-oxalacetic transaminase（AST） not greater than 2.5x ULN; Creatinine clearance no less than 60ml/min * Peripheral venous channel open and no contraindications to separating lymphocytes * Negative pregnancy test for women of childbearing potential, and patients must be willing to practice birth control during the regimen * Provision of informed consent * Be able to follow the research program and follow up process
Exclusion criteria
* Those who now are undergoing other antitumor drug therapy (including chemotherapy, systemic steroids therapy, surgery, target therapy or immune therapy); * Prior treatment with PD-1 monoclonal antibody(mAb） or PD-L1 mAb; * Prior malignancy active within the previous 5 years except for locally curable cancers that have been apparently cured, such as basal cell skin cancer or carcinoma in situ of the cervix; * History with pulmonary tuberculosis, and positive tests for Acquired Immune Deficiency Syndrome(HIV),hepatitis C virus(HCV),hepatitis B virus(HBV); * Patients with any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, such as hypophysitis, pneumonia, colitis, hepatitis, nephritis, hyperthyroidism or hypothyroidism; Severe, uncontrolled medical condition that would affect patients' compliance or obscure the interpretation of toxicity determination or adverse events, including active severe infection, uncontrolled diabetes, angiocardiopathy (heart failure \> class II New York Heart Association(NYHA), heart block \>II grade, myocardial infarction, unstable arrhythmia or unstable angina within past 6 months, cerebral infarction within past 3 months) or pulmonary disease ( interstitial pneumonia, obstructive pulmonary disease or symptomatic bronchospasm). * Evidence with central nervous system(CNS) disease * Pregnant or nursing * Psychiatric medicines abuse without withdrawal, or history of psychiatric illness. * Hypersensitivity to investigational drugs or its components.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with Adverse Events | up to 6 months | using Common Terminology Criteria for Adverse Events (CTCAE v4.0) in patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response Rate | At 3, 6 and 12 months | Response Rate（RR） will be evaluated according Response Evaluation Criteria in Solid Tumors |
| Progression free survival (PFS) | At 6,9 and 12 months | the duration of progression free survival is measured from the time of treatment to the first date that recurrent or progressive disease or for any reason of death is objectively documented. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | At 6,12 and 18 months | the duration is measured from the time of treatment to the time of death |
| Interferon-gama change of PBMC cells in the peripheral blood stimulated by tumor antigens | At baseline,40days,2 months,6 months and at the time of disease progress | T cells in the peripheral blood stimulated by tumor antigens for 24 hr，and then Interferon-gama secretion is measured |
| Th1/Th2 change in the peripheral blood | At baseline,40days,2 months,6 months and at the time of disease progress | cytokines are measured by flow cytometry(FCM) |
Countries
China
Contacts
Primary ContactBaorui Liu, M.D & Ph.D
Backup ContactZhengyun Zou, M.D & Ph.D
Outcome results
None listed